
    
      High risk acute leukemia patients (except t(9;22)(q34; q11) cytogenetic abnormalities.)
      received interferon Î±-2b after prophylactic DLI at day 30-60 after unmanipulated blood and
      marrow transplantation. The end points were safety, leukemia-free survival, and immunologic
      response. Following time is 12 months.
    
  